Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation

Nobuaki Ochi1,2, Hiromichi Yamane1, Katsuyuki Hotta3, Hiromi Fuji4, Hideo Isozaki2,5, Yoshihiro Honda1,2, Tomoko Yamagishi1, Toshio Kubo6, Mitsune Tanimoto2,3, Katsuyuki Kiura4, Nagio Takigawa1

1Department of General Internal Medicine 4, Kawasaki Hospital, Kawasaki Medical School, Okayama, Japan; 2Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; 3Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan; 4Department of Pharmacy, Kawasaki Medical School, Okayama, Japan; 5Department of Clinical Pharmaceutics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; 6Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

Introduction: Widespread use of generic drugs is considered to be indispensable if reductions in total health care costs are to be achieved, but the market share of such drugs remains low. In general, generic drugs have the same active ingredients as brand-name drugs, but this is not always the case. Thus, toxicity profiles may vary when brand-name and generic drugs are compared. We retrospectively investigated the incidence of hyponatremia in patients receiving brand-name cisplatin (CDDP) and a generic counterpart thereof.

Methods: We reviewed the medical records of patients treated with brand-name CDDP (n=53) and a generic formulation (n=26), and compared the incidences of hyponatremia and renal toxicity. Toxicities were graded using the Common Terminology Criteria for Adverse Events, version 4.0. Differences between groups were evaluated using the Student’s t-test, and the odds ratio for hyponatremia was estimated via logistic regression analysis.

Results: Serum creatinine levels after chemotherapy increased significantly in both the brand-name and generic CDDP groups; no significant difference was evident between the two groups. Hyponatremia of grade 3 or above developed in 30.7% of the generic CDDP group compared to 15.1% of the brand-name CDDP group (P=0.011). Multivariate analysis showed that the use of generic CDDP increased the incidence of hyponatremia (odds ratio =5.661, 95% confidence interval =1.403–22.839; P=0.015).

Conclusion: Oncologists should be aware that use of a generic CDDP might be associated with more hyponatremia than would use of brand-name CDDP.

Keywords: cisplatin, hyponatremia, brand-name, generic drug

Introduction

Generic drugs containing the same active ingredients as the original brand-name products have been developed and prescribed worldwide. Widespread use of such drugs is considered to be indispensable to reduce health care costs.1 However, the market share of generic drugs is not yet sufficiently large to notably decrease the total health care expenditure in many developed countries. One reason is that both patients and physicians are unsure that the effects and safety profiles of generic drugs are truly similar to those of brand-name drugs. As generics contain the same active ingredients as brand-name drugs, the bioavailability of a generic is generally assumed to be the same as that of the brand-name drug, and no additional clinical trials are performed.

Cisplatin (CDDP) is one of the most active antineoplastic drugs prescribed to treat various solid tumors, including lung, gastric, head and neck, and bladder cancers. CDDP remains the principal drug of choice for treatment of these malignancies despite the development of many novel anticancer drugs over the past several decades.2,3 However, CDDP induces many adverse effects, including nausea, vomiting, appetite loss, renal
toxicity, and neurotoxicity. The “syndrome of inappropriate secretion of antidiuretic hormone” (SIADH) is a less common but important toxicity that is sometimes fatal. CDDP-induced hyponatremia has also occurred in case of renal salt-wasting syndrome, in patients with nausea/vomiting/anorexia, and when vigorous hydration was administered to prevent nephrotoxicity. It is sometimes difficult to accurately diagnose the cause of hyponatremia because various contributing factors can interact in a complex manner.

To date, a few reports have explored differences in the renal toxicities of brand-name and generic CDDP. Here, we focused on the frequency of hyponatremia induced by a generic CDDP compared with its brand-name counterpart.

Materials and methods

Patient selection

We searched for patients receiving CDDP-containing regimens from January 2009 to April 2010 at Okayama University Hospital and from April 2011 to March 2013 at Kawasaki Hospital, both in Okayama, Japan. Over these respective periods, the two hospitals prescribed both brand-name and generic CDDP. Patients were retrospectively selected using the following criteria: 1) histologically or cytologically diagnosed malignancy; 2) no prior chemotherapy with a CDDP-containing regimen; 3) chemotherapy with a regimen that included more than 60 mg of CDDP on day 1; and 4) a baseline sodium concentration >130 mEq/L. Patients receiving concurrent radiation therapy were excluded. Both groups received their CDDP-containing treatments in the context of a short-duration hydration setting. To avoid interactions between hydration settings, we extracted additional patients who received treatment with a brand-name CDDP-containing regimen under standard hydration conditions (approximately 3,000 mL on day 1) from September 2007 to December 2008 in Okayama University Hospital. We selected this period because NO and NT, who hold board certificates for medical oncology, worked at Okayama University Hospital at that time. We could treat patients with only board-name CDDP at Okayama University, and with only generic CDDP at Kawasaki Hospital in the respective periods because of availability of the drugs. This study was approved by the Kawasaki Medical School Ethics Committee (#1636) and Okayama University Hospital Ethics Committee (#1889).

Data collection process and data items

To avoid bias in data abstraction, four medical staff (YH, HF, HI, and NO) independently abstracted data from electronic medical records and subsequently compared their results. The following information was obtained from each report: date of treatment administration; treatment regimen; dose of CDDP; and patient characteristics (age, sex, underlying malignancy, performance status [PS], duration of hyponatremia, pretreatment and posttreatment serum sodium concentrations, serum creatinine level, serum potassium level, and body surface area). Serum biochemical levels were measured using automatic analyzers (Biomajesty™ JCA-BM series; JEOL, Tokyo, Japan) in both institutes.

Treatment schedule

Patients treated with brand-name and generic CDDP under short-duration hydration conditions were classified into groups 1 and 3, respectively, and patients treated with brand-name CDDP using standard hydration were defined as group 2. Briefly, the short hydration regimen for groups 1 and 3 was as follows. Antiemetic prophylaxis consisted of a 5-hydroxytryptamine 3 (5-HT3) receptor antagonist and dexamethasone, with or without an aprepitant, and was given before chemotherapy. For prehydration and posthydration, 5 mEq potassium chloride and 4 mEq magnesium sulfate in 500 mL of half saline solution were infused at a rate of 500 mL/hour. Next, cytotoxic agents (docetaxel, pemetrexed, irinotecan, vinorelbine, gemcitabine, etoposide, or topotecan), in 100–250 mL of normal saline, were administered, followed by 40 g mannitol (to trigger diuresis) 15 minutes later, and an appropriate dose of CDDP in 250 mL of normal saline 1 hour later. At least 1,000 mL of water was taken orally on days 2 and 3; this was mandatory because traditional intravenous hydration was not performed.

Definition of hyponatremia

Hyponatremia was defined and graded using the Common Terminology Criteria for Adverse Events, version 4.0, as follows: a serum sodium concentration from lower limit of normal to 130 mEq/L, grade 1; <130–120 mEq/L, grade 3; <120 mEq/L, grade 4; and death from hyponatremia, grade 5. We graded all patients using these criteria. We collected laboratory data and information on patient characteristics from electronic medical databases.

Statistical analysis

Differences between the two groups were evaluated using Student’s t-tests (paired and unpaired) to compare parametric data and the Wilcoxon signed-rank test or Mann–Whitney U-test to compare nonparametric data. Differences between groups were evaluated via one-way analysis of variance. The Bonferroni test was applied when multiple comparisons were performed. Relationships between serum sodium concentrations and patient characteristics were analyzed via linear regression. Odds ratios with 95% confidence intervals...
(CIs) for development of hyponatremia, by strata of patient characteristics, were estimated via logistic regression. Such analyses were weighted by the delta serum sodium concentration (ΔNa), defined as the difference between the prechemotherapy serum sodium concentration and the minimum sodium concentration. A positive ΔNa (>0) meant that the serum sodium concentration decreased during treatment. All P-values were obtained by two-sided testing, and the significance level was set at P<0.05. Statistical analyses were conducted using the Stata software (version 12; StataCorp, College Station, TX, USA).

Results
A total of 79 patients met the study criteria, of whom 53 received brand-name CDDP, 27 via short hydration (group 1) and 26 via standard hydration (group 2). A total of 26 patients were treated with generic CDDP via short hydration (group 3). Patient characteristics are shown in Table 1. No significant difference in any of age, PS, the number of drug regimens given, or baseline serum sodium concentration was evident between groups 1 and 3. The proportion of male patients in group 1 (88.9%) was significantly higher than in group 3 (53.8%).

Hyponatremia status and serum creatinine levels after chemotherapy are shown in Table 2. No treatment-related death was noted. Grade 3 (19.2%) and grade 4 (11.5%) hyponatremia were observed in group 3, whereas grade 4 hyponatremia was not detected in groups 1 or 2. The ΔNa value (7.5 mEq/L) in group 3 was marginally higher than that (6.0 mEq/L) in group 1 (P=0.05). Hyponatremia of grade 3 or above occurred in 30.7% of the generic CDDP group (group 3) compared to 15.1% of the brand-name CDDP group (groups 1 and 2) (P=0.011). The mean minimum sodium concentrations were 129.5 mEq/L in the generic CDDP group and 132.7 mEq/L in the brand-name CDDP group (Figure 1A). When the three groups were compared, the sodium concentration in group 3 was significantly lower than in group 1 (P=0.034). However, no significant difference was evident between groups 1 and 2 (Figure 1B). These results suggest that hyponatremia might be induced not by short hydration but rather by use of generic CDDP.

Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Group 1 (n=27)</th>
<th>Group 2 (n=26)</th>
<th>Group 3 (n=26)</th>
<th>Total (n=79)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>62.8</td>
<td>58.3</td>
<td>63.8</td>
<td>61.6</td>
<td>0.67</td>
</tr>
<tr>
<td>Range</td>
<td>35.1–78.5</td>
<td>33.0–76.7</td>
<td>37.1–74.6</td>
<td>33.0–78.5</td>
<td></td>
</tr>
<tr>
<td>Performance status (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥1</td>
<td>81.5</td>
<td>61.5</td>
<td>80.8</td>
<td>74.7</td>
<td>0.63</td>
</tr>
<tr>
<td>Sex, male (%)</td>
<td>88.9</td>
<td>80.8</td>
<td>53.8</td>
<td>69.6</td>
<td>&lt;0.01†</td>
</tr>
<tr>
<td>Treatment line</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.04</td>
</tr>
<tr>
<td>Range</td>
<td>1–6</td>
<td>1–6</td>
<td>1–9</td>
<td>1–9</td>
<td></td>
</tr>
<tr>
<td>Serum sodium concentration (mEq/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>139</td>
<td>139</td>
<td>139</td>
<td>139</td>
<td>0.37</td>
</tr>
<tr>
<td>Range</td>
<td>130–143</td>
<td>136–144</td>
<td>133–141</td>
<td>130–144</td>
<td></td>
</tr>
<tr>
<td>Serum potassium concentration (mEq/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>4.10</td>
<td>4.20</td>
<td>4.25</td>
<td>4.20</td>
<td>0.48</td>
</tr>
<tr>
<td>Range</td>
<td>3.6–5.1</td>
<td>3.8–4.9</td>
<td>3.2–5.4</td>
<td>3.2–5.4</td>
<td></td>
</tr>
<tr>
<td>Serum creatinine level (mg/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>0.79</td>
<td>0.75</td>
<td>0.63</td>
<td>0.72</td>
<td>&lt;0.05†</td>
</tr>
<tr>
<td>Range</td>
<td>0.5–1.07</td>
<td>0.44–1.10</td>
<td>0.44–1.18</td>
<td>0.44–1.18</td>
<td></td>
</tr>
<tr>
<td>Cisplatin dose (mg/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.05†</td>
</tr>
<tr>
<td>Mean</td>
<td>65.8</td>
<td>67.6</td>
<td>71.5</td>
<td>68.2</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>54.5–80.1</td>
<td>53.6–83.4</td>
<td>55.4–84.7</td>
<td>53.6–84.7</td>
<td></td>
</tr>
</tbody>
</table>

Notes: *P-values were assessed between groups 1 and 3 by two-sample Wilcoxon rank sum test or unpaired Student’s t-test. †Statistically significant at P<0.05.

Abbreviations: LCNEC, large-cell neuroendocrine carcinoma; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.
Serum creatinine concentrations after chemotherapy (the maximum values attained during chemotherapy) increased uniformly, with statistical significance, in all groups (Figure 2A). Baseline serum creatinine levels were slightly but significantly higher in the brand-name CDDP group ($P=0.0124$); however, no significant between-group difference was evident in serum creatinine levels after chemotherapy (Figure 2B). To exclude any effect of hydration, we focused on serum creatinine changes in groups 1 and 3. The increases in serum creatinine levels did not differ between these groups (Figure 2C), indicating that the extents of renal toxicity were similar, regardless of the CDDP formulation used. Also, sex did not affect the results (Figure 2D).

**Table 2** Hyponatremic status and serum creatinine levels after chemotherapy

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group 1 (n=27)</th>
<th>Group 2 (n=26)</th>
<th>Group 3 (n=26)</th>
<th>Total (n=79)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum serum sodium concentration (mEq/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>134.0</td>
<td>132.5</td>
<td>130.5</td>
<td>133.0</td>
<td>&lt;0.05†</td>
</tr>
<tr>
<td>Range</td>
<td>122–139</td>
<td>121–138</td>
<td>112–138</td>
<td>112–139</td>
<td></td>
</tr>
<tr>
<td>Hyponatremia (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>44.4</td>
<td>57.7</td>
<td>50.0</td>
<td>50.6</td>
<td></td>
</tr>
<tr>
<td>Grade 2</td>
<td>14.8</td>
<td>15.4</td>
<td>19.2</td>
<td>16.5</td>
<td></td>
</tr>
<tr>
<td>Grade 4</td>
<td>0.0</td>
<td>0.0</td>
<td>11.5</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td>$\Delta$Na (mEq/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>6.0</td>
<td>6.5</td>
<td>7.5</td>
<td>6.0</td>
<td>0.05†</td>
</tr>
<tr>
<td>Range</td>
<td>1–19</td>
<td>2–22</td>
<td>1–28</td>
<td>1–28</td>
<td></td>
</tr>
<tr>
<td>Duration (day)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>6.0</td>
<td>7.0</td>
<td>7.8</td>
<td>7.0</td>
<td>0.41</td>
</tr>
<tr>
<td>Range</td>
<td>3–33</td>
<td>4–46</td>
<td>3–33</td>
<td>3–46</td>
<td></td>
</tr>
<tr>
<td>Post-serum creatinine level (mg/dl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>0.86</td>
<td>0.97</td>
<td>0.68</td>
<td>0.89</td>
<td>0.44</td>
</tr>
<tr>
<td>Range</td>
<td>0.51–1.76</td>
<td>0.63–1.66</td>
<td>0.45–1.75</td>
<td>0.45–1.76</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** *P*-values were assessed between groups 1 and 3 by unpaired Student’s t-test. †Statistically significant at $P<0.05$.

**Abbreviation:** $\Delta$Na, difference between the prechemotherapy serum sodium concentration and the minimum sodium concentration.

*Figure 1* Minimum serum sodium concentrations during chemotherapy.

**Notes:** Box-and-whisker plots. The bottom and top of each box are the 25th and 75th percentiles (the lower and upper quartiles, respectively), and the band near the middle of each box is the 50th percentile (the median). Comparisons of minimum serum sodium concentrations (A) between those receiving brand-name CDDP (groups 1 and 2) and generic CDDP (group 3) and (B) among all three groups. $^*$Significant at $P<0.05$.

**Abbreviations:** ANOVA, analysis of variance; CDDP, cisplatin; NS, not significant.
Linear regression analyses revealed no significant influence of any patient characteristic (age, baseline serum creatinine level, or CDDP dose) on serum sodium concentration in the two groups (Figure 3). The serum sodium concentration tended to decrease in patients with low baseline sodium concentrations (the regression coefficient was 0.73; \( P=0.051 \)), indicating that a patient lost 0.73 mEq/L serum sodium upon brand-name CDDP treatment with each decrement of 1.0 mEq/L at a baseline serum sodium concentration. In other words, \( \Delta Na \) values in patients receiving brand-name CDDP seemed to remain constant irrespective of baseline sodium concentrations, whereas use of generic CDDP seemed to unexpectedly decrease the sodium concentration regardless of the baseline concentration (Figure 3B).

We further explored key factors influencing development of grade 3 or 4 hyponatremia. All variables were dichotomized into two classes, on the basis of median or mean values. Univariate and multivariate analyses of several variables are shown in Table 3. Generic CDDP use was associated with a trend toward hyponatremia, but without statistical significance (odds ratio = 2.888, 95% CI = 0.837–9.966; \( P=0.093 \)), upon univariate analysis. Although patients with low baseline serum sodium concentrations (<139 mEq/L) developed grade 3 or 4 hyponatremia more frequently, this was not statistically significant (odds ratio = 2.348, 95% CI = 0.701–7.860; \( P=0.166 \)). Multivariate analysis revealed that generic CDDP use was associated with a 5.661-fold increased risk of hyponatremia (95% CI = 1.403–22.839; \( P=0.015 \)). Also, old age (\( \geq 70 \) years) and poor PS (1 or...
Table 3 Univariate and multivariate analysis of variables

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate analysis</th>
<th>Multivariate analysis*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds ratio</td>
<td>P-value</td>
</tr>
<tr>
<td>Male</td>
<td>0.355</td>
<td>0.103</td>
</tr>
<tr>
<td>Age ≥70 years</td>
<td>1.505</td>
<td>0.713</td>
</tr>
<tr>
<td>PS ≥1</td>
<td>0.624</td>
<td>0.493</td>
</tr>
<tr>
<td>Generic CDDP</td>
<td>2.888</td>
<td>0.093</td>
</tr>
<tr>
<td>Short hydration</td>
<td>1.855</td>
<td>0.375</td>
</tr>
<tr>
<td>Baseline sodium concentration &lt;139 mEq/L</td>
<td>2.348</td>
<td>0.166</td>
</tr>
<tr>
<td>Baseline creatinine concentration ≥0.72 mg/dL</td>
<td>0.619</td>
<td>0.451</td>
</tr>
<tr>
<td>CDDP dose ≥70 mg/m²</td>
<td>0.674</td>
<td>0.526</td>
</tr>
</tbody>
</table>

Notes: *Stepwise multiple regression analysis. †Variable was removed because of no significance for analysis.
Abbreviations: CI, confidence interval; CDDP, cisplatin; PS, performance status.

Discussion

We found that the incidence of hyponatremia increased significantly in patients treated with a generic CDDP rather than brand-name CDDP. In contrast, the incidence of renal damage was similar in the two groups. Use of a generic CDDP significantly increased the frequency of grade 3 or 4 hyponatremia (odds ratio = 5.661).

The question of whether generic drugs are truly equivalent to brand-name drugs has often been debated. When an application for release of a brand-name drug is made, the US Food and Drug Administration (FDA) requires drug manufacturers to submit large amounts of preclinical and clinical data on safety and efficacy and, in most cases, requires clinical data from large-scale trials conducted in the intended patient populations. However, an application for release of a generic drug need not be accompanied by the same amount of clinical safety and efficacy data; it is necessary only to demonstrate that the bioavailability and bioequivalence are equivalent to those of...
the brand-name drug.\textsuperscript{9} Furthermore, the FDA generally allows
generic drug peak plasma concentration, and the area under
the plasma drug concentration versus time curve (the AUC),
to vary by \textminus20\% to +25\% compared to the brand-name drug.\textsuperscript{5}
It is possible that such variation may render the efficacy and
safety of generic drugs different from those of their brand-name
counterparts. Any increase in toxicity or reduction in efficacy
upon slight dose escalation or reduction is of concern, because
the dosages of anticancer drugs are finely adjusted by reference
to the body surface area or body weight of patients.

A large-scale retrospective analysis of the bioequivalence
data on generic and brand-name drugs, accumulated over a
12-year period, showed that the average differences in peak
plasma concentration and AUC values between generic and
brand-name products were 4.35\% and 3.56\%, respectively.\textsuperscript{10}
It was concluded that generic drugs were therapeutically
equivalent to their brand-name counterparts. However, when
differences between brand-name drugs and their generic
counterparts used in the fields of cardioangiology,\textsuperscript{1,11–13}
psychiatry,\textsuperscript{14–17} and endocrinology\textsuperscript{18–20} were compared, the
results were controversial.

Possible differences between brand-name and generic
drugs delivered via injection have received less attention.\textsuperscript{6,7,21–27}
Generic and brand-name drugs contain the same active
ingredients and exhibit similar pharmacokinetics. However,
the drugs may differ in terms of safety and toxicity profiles
because some of the inactive ingredients vary. Most generic
formulations of docetaxel contained a lower drug concentra-
tion than the brand-name formulation (less than 90\%
of that expected in some instances) and/or high levels of
impurities absent from the brand-name drug.\textsuperscript{22} In vivo stud-
ies have shown that the blood levels of some liver enzymes
increased in those taking generic paclitaxel but not the brand-
name drug, but no significant differences in neurotoxicity,
hypersensitivity, or vascular pain were evident.\textsuperscript{25,28}

As is also true of other antineoplastic drugs, CDDP-induced
toxicity has been mentioned frequently in the literature, but few
reports have explored differences between generic and brand-
name formulations. Recently, differences in renal toxicities
have been reported. Sekine et al\textsuperscript{22} found that grade 2 or 3 renal
toxicity was more frequently observed in male patients taking
the generic formulation, because their hydration volumes were
relatively low. Another large-scale retrospective study found
that grade 1 renal toxicity was significantly more frequent in
the generic CDDP group, but the incidences of grade 2 or 3
toxicities did not differ between those taking the two CDDP
formulations.\textsuperscript{7} In our present study, we found no significant
among-group difference in renal toxicity. Differences in the
hematological toxicities of brand-name and generic CDDP
have also been investigated retrospectively. In patients with
cervical cancer, the number experiencing grade 3 or 4 leuko-
penia was significantly greater in the generic than in the brand-
name group.\textsuperscript{27} We focused on renal toxicity and hyponatremia
in the present study, but other toxicities – including hemat-
ological toxicity – should be investigated in future studies. Like
docetaxel described above, generic cisplatin might have some
impurities that the brand-name cisplatin does not have. It is
very important to find out whether the brand-name cisplatin has
better quality control and whether any impurities have inter-
ferred with the therapy. A further study including heavy-metal
analysis should be performed in order to clarify this.

Our present study had several limitations. First, this
was a small retrospective study; thus, a larger randomized
study should be performed to confirm our results. Realisti-
cally, a prospective observational study might be preferable.
Second, because we included all consecutive patients who
were eligible, all of the nature of underlying malignancies,
the extent of hyponatremia before chemotherapy, and the
chemotherapeutic drug combinations prescribed differed
slightly among the groups. The other combined agent and
some of the diseases, such as brain tumors, could account
for hyponatremia, including SIADH. It is preferable to unify
the chemotherapeutic regimen, underlying malignancies, and
disease stages in any further observational study, as our results
may have been affected by such differences. Third, we had the
data such as urinary sodium concentration and osmolality only
in several patients. Thus, the causes of hyponatremia were not
extensively examined. SIADH, renal salt-wasting syndrome,
and salt loss caused by vomiting and/or anorexia, should be
diagnosed as accurately as possible in future studies.

In conclusion, generic CDDP may cause hyponatremia
more frequently than the brand-name drug because of slight
differences in active or inactive ingredients. Generic drugs
have been widely used worldwide and contribute to reductions
in health care costs. However, clinicians should be aware that
the use of generic drugs often requires a trade-off between
cost-effectiveness and assured safety, because off-patent
drugs are generally approved for sale without the performance
of further expensive and time-consuming clinical trials.

Acknowledgement

We thank Dr Yasumasa Monobe, Department of Pathology 1,
Kawasaki Hospital, Kawasaki Medical School, Okayama,
Japan, who confirmed the diagnoses of malignancies.

Disclosure

KH has received honoraria from Eli Lilly Japan, Taiho
Pharmaceutical, Chugai Pharmaceutical, and Sanofi-Aventis.
KK has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Sanofi-Aventis. NT has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer Inc. Japan, Boehringer–Ingelheim in Japan, and Sanofi-Aventis. The authors report no other conflicts of interest in this work.

References


